89bio Announces Closing of its Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

<p>SAN FRANCISCO, Dec. 12, 2023 (GLOBE NEWSWIRE) &#8212; 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that it closed its previously announced upsized underwritten public offering of 17,567,567 shares of its common stock, including the [&#8230;]</p>
<p>The post <a href="https://forextv.com/top-news/89bio-announces-closing-of-its-upsized-public-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-shares/">89bio Announces Closing of its Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares</a> appeared first on <a href="https://forextv.com">ForexTV</a>.</p>